Evidence map›Paper›PMID 39334904›Full record

ArticleBiomolecules2024

Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes.

Elham Kayvanpour, Farbod Sedaghat-Hamedani, Daniel Tian Li, Tobias Miersch, Tanja Weis, Imo Hoefer, Norbert Frey, Benjamin Meder

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elham KayvanpourDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.ORCID 0000-0001-7285-2825
Farbod Sedaghat-HamedaniDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.ORCID 0000-0002-3266-0527
Daniel Tian LiDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.
Tobias MierschDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.ORCID 0000-0002-0453-0960
Tanja WeisDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.
Imo HoeferExperimental Cardiology Laboratory, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.
Norbert FreyDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.
Benjamin MederDepartment of Medicine III, University of Heidelberg, INF 410, 69120 Heidelberg, Germany.

Funding

DZHK 81X3500117
6 · The paper itself

Abstract

backgroundDilated cardiomyopathy (DCM) involves myocardial remodeling, characterized by significant fibrosis and extracellular matrix expansion. These changes impair heart function, increasing the risk of heart failure and sudden cardiac death. This study investigates the prognostic value of circulating fibrosis biomarkers as a less invasive method in DCM patients.

methodsPlasma samples from 185 patients with confirmed DCM were analyzed to measure 13 circulating biomarkers using Luminex bead-based multiplex assays and ELISA. The prognostic value of these biomarkers was evaluated concerning heart failure-associated events and all-cause mortality.

resultsElevated MMP-2 levels (>1519.3 ng/mL) were linked to older age, higher diabetes prevalence, lower HDL, increased NT-proBNP and hs-TnT levels, and severe systolic dysfunction. High TIMP-1 levels (>124.9 ng/mL) correlated with elevated NT-proBNP, more atrial fibrillation, reduced exercise capacity, and larger right ventricles. Increased GDF-15 levels (>1213.9 ng/mL) were associated with older age, systemic inflammation, renal impairment, and poor exercise performance. Elevated OPN levels (>81.7 ng/mL) were linked to higher serum creatinine and NT-proBNP levels. Over a median follow-up of 32.4 months, higher levels of these biomarkers predicted worse outcomes, including increased risks of heart failure-related events and mortality.

conclusionsCirculating fibrosis biomarkers, particularly MMP-2, TIMP-1, GDF-15, and OPN, are valuable prognostic tools in DCM. They reflect the severity of myocardial remodeling and systemic disease burden, aiding in risk stratification and therapeutic intervention. Integrating these biomarkers into clinical practice could improve DCM management and patient prognosis.

Indexed as

BiomarkersCardiomyopathy, DilatedFibrosisGrowth Differentiation Factor 15OsteopontinPeptide FragmentsTissue Inhibitor of Metalloproteinase-1AdultAgedFemaleHeart FailureHumansMaleMatrix Metalloproteinase 2Middle AgedNatriuretic Peptide, BrainBiomarkersGDF15 protein, humanGrowth Differentiation Factor 15Matrix Metalloproteinase 2MMP2 protein, humanNatriuretic Peptide, BrainOsteopontinPeptide Fragmentspro-brain natriuretic peptide (1-76)SPP1 protein, humanTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1biomarkerscardiac fibrosisdilated cardiomyopathyGDF-15MMP-2OPNTIMP-1

Identifiers

PMID39334904
PMCPMC11430616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.